Medical device company, Tepha, has entered a royalty obligations agreement with pharmaceutical company, Metabolix, to use the latter’s biopolymer technology in certain medical applications.
As part of the agreement, which also includes two additional Metabolix production strains and related IP, Tepha will pay Metabolix $2m in order to avoid future royalties.
Go deeper with GlobalData
HTG Molecular Diagnostics and Merck KGaA have signed a broad companion diagnostics master agreement.
The initial development programme under the agreement involves using the former’s EdgeSeq DLBCL cell of origin assay in the latter’s development programme of M7583, a selective and irreversible inhibitor of Burton’s Tyrosine Kinase (BTK).
Midatech Pharma has raised £16m ($19.83m) through a private placement of its common stock shares, which was oversubscribed to by its existing and new investors.
See Also:
The company has also raised £12m ($14.87m) in another private placement of its common stock shares.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe proceeds will be used by the company to expand and advance product development pipeline, to invest in its manufacturing and commercial platform and for working capital expenses.
